Clinical Trials on Unresectable/Metastatic Melanoma in New Zealand

Total 2463 results

Amgen

Completed

Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec

Melanoma

United States, Canada
Hoffmann-La Roche

Completed

Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma

Malignant Melanoma

United States, Australia, Brazil, Spain, South Africa, Ukraine, Bosnia and Herzegovina
Memorial Sloan Kettering Cancer Center

Completed

Study Using High-Dose Single Fraction Image-Guided Radiotherapy for Metastatic Lesions to Soft Tissue Masses, Lymph Node, or Bone

Metastatic Disease

United States
Memorial Sloan Kettering Cancer Center
Genentech, Inc.

Terminated

Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation

Melanoma

United States
National Cancer Institute (NCI)

Completed

Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Refractory Malignant Solid Neoplasm | Recurrent Melanoma | Recurrent Malignant Solid Neoplasm | Recurrent Neuroblastoma | Recurrent Non-Hodgkin... and other conditions

United States, Canada
National Cancer Institute (NCI)

Completed

Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery

Locally Advanced Epithelioid Hemangioendothelioma | Metastatic Epithelioid Hemangioendothelioma | Unresectable Epithelioid Hemangioendothelioma

United States
Merck Sharp & Dohme LLC
Eisai Inc.

Completed

Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004)

Advanced Melanoma

Canada, United States, Australia, Spain, Sweden
GlaxoSmithKline

Completed

Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF Inhibitor

Cancer

Australia, United States
Ruhr University of Bochum

Completed

miRNA Machinery in Melanoma, Melanoma Metastases and Benign Melanocytic Naevi

Cutaneous Melanoma | Nevi

Germany
Array Biopharma, now a wholly owned subsidiary...

Terminated

A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma

Uveal Melanoma

United States, France, Germany, Netherlands, Spain, United Kingdom
Bristol-Myers Squibb

Completed

Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma

Melanoma

United States
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of Tumor Imaging With Multispectral Optoacoustic Tomography

Melanoma | Breast Cancer

United States, Germany
National Cancer Institute (NCI)

Active, not recruiting

A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma

Clinical Stage III Cutaneous Melanoma AJCC v8 | Mucosal Melanoma | Acral Lentiginous Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8

United States
Bristol-Myers Squibb

Completed

Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma

High Risk Stage III Melanoma

Italy, Poland, United Kingdom, United States, Netherlands, Spain, Australia, France, Germany, Canada, Russian Federation, Belgium, Norway, Switzerland, Sweden, Finland, Austria, Denmark, Czechia
GlaxoSmithKline

Completed

Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma

Melanoma

Australia, United States
Bristol-Myers Squibb

Completed

Study of Autoimmune Disease Complications Following Ipilimumab Treatment Among Melanoma Patients With Underlying Autoimmune Diseases

Melanoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery

Stage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Melanoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Melanoma of Unknown Primary | Stage IIIB Cutaneous Melanoma AJCC v7

United States, Canada
National Cancer Institute (NCI)

Completed

Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery

Recurrent Melanoma | Stage IV Melanoma

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0508: Thalidomide and Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery

Melanoma (Skin)

United States
NewLink Genetics Corporation

Terminated

A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma (NLG2107)

Melanoma

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
Aura Biosciences

Recruiting

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma (CoMpass)

Ocular Melanoma | Uveal Melanoma | Choroidal Melanoma | Indeterminate Lesions

United States, Australia, United Kingdom
Agenus Inc.

Completed

Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma

Malignant Melanoma

United States, Australia, Poland, Ukraine, United Kingdom, Russian Federation, Hungary, Italy, Sweden
Melanoma and Skin Cancer Trials Limited
Trans Tasman Radiation Oncology Group

Active, not recruiting

Neurotropic Melanoma of the Head and Neck (RTN2)

Melanoma

United States, Australia, United Kingdom
University of Rochester

Completed

A Study For Using Radiosurgery On Limited Metastases

Neoplasms, Metastatic

United States
Melanoma and Skin Cancer Trials Limited
Norfolk and Norwich University Hospitals NHS Foundation Trust; Peter MacCallum...

Active, not recruiting

MelmarT Melanoma Margins Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma (MelMarT)

Cutaneous Melanoma by AJCC V7 Stage

United Kingdom, United States, Sweden, Australia, Canada
Southwest Oncology Group
National Cancer Institute (NCI); Eastern Cooperative Oncology Group; Children... and other collaborators

Completed

S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma

Melanoma (Skin)

United States, Australia
Immune Design

Terminated

Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

Melanoma | Sarcoma | Ovarian Cancer | Non-small Cell Lung Cancer

United States
Relay Therapeutics, Inc.

Active, not recruiting

First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors

Breast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Solid Tumor, Adult | HER2-negative Breast Cancer | Hormone Receptor Positive Tumor | Unresectable Solid Tumor | PIK3CA Mutation

United States
Celgene
University of Arizona

Completed

A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma

Malignant Melanoma

Canada, United States, Australia, United Kingdom, France, Italy, Spain, Germany, Netherlands
Actelion

Completed

Effect of Bosentan in Patients With Metastatic Melanoma Treated With Dacarbazine (DTIC)

Melanoma

Australia
Milton S. Hershey Medical Center
Emory University; Vassar Brothers Medical Center

Completed

SPY-X: A Study to Assess the Feasibility of Using SPY Alone for Sentinel Node Localization for Melanoma or Breast Cancer (SPYX)

Breast Cancer | Sentinel Lymph Node | Melanoma (Skin)

United States
Provectus Biopharmaceuticals, Inc.

Active, not recruiting

PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma

Melanoma

United States
Novartis Pharmaceuticals

Completed

EPO906 Therapy in Patients With Advanced Melanoma

Melanoma

United States
New Mexico Cancer Care Alliance

Terminated

Carboplatin, Paclitaxel, and Temozolomide for Patients With Metastatic Melanoma

Melanoma

United States
New Mexico Cancer Care Alliance

Terminated

Ultraviolet Light Exposure and Immunosuppression in Cutaneous Melanoma

Melanoma

United States
National Cancer Institute (NCI)
Exelisis

Completed

Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery

Stage IV Uveal Melanoma AJCC v7 | Recurrent Uveal Melanoma | Stage III Uveal Melanoma AJCC v7 | Stage IIIA Uveal Melanoma AJCC v7 | Stage IIIB Uveal Melanoma AJCC v7 | Stage IIIC Uveal Melanoma AJCC v7

United States, Canada
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma

Neuroblastoma | Localized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Ganglioneuroblastoma

United States, Canada, Saudi Arabia, Puerto Rico, Australia, New Zealand
Hoffmann-La Roche

Completed

A Study of Vemurafenib in Participants With Metastatic Melanoma

Malignant Melanoma

Canada, Spain, United Kingdom, Hungary, Australia, Austria, Belgium, Ecuador, Estonia, Finland, Ireland, Italy, Korea, Republic of, Mexico, Netherlands, Portugal, Slovenia, Sweden, Turkey, Brazil, India, Germany, Bosnia and Herzegovina and more
Memorial Sloan Kettering Cancer Center
Repare Therapeutics

Recruiting

A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer

Solid Tumor | Metastatic Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer

Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Advanced Malignant Solid Neoplasm | Stage IIIC Cutaneous Melanoma AJCC v7 | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7 | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma... and other conditions

United States
AstraZeneca

Completed

Study to Compare Two Formulations of CP-675,206 Monoclonal Antibody

Melanoma

United States
National Cancer Institute (NCI)

Recruiting

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma

Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7

United States
Weill Medical College of Cornell University

Terminated

RFA RCT for Pancreatic or Bile Duct Cancer (RFARCT)

Cholangiocarcinoma Non-resectable | Unresectable Pancreatic Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Dinaciclib in Treating Patients With Stage IV Melanoma

Stage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Melanoma | Lentigo Maligna Melanoma | Mucosal Melanoma | Acral Lentiginous Melanoma | Cutaneous Nodular Melanoma | Low-CSD Melanoma

United States
Bristol-Myers Squibb

Completed

An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy

Locally Advanced (Unresectable) or Metastatic Adenocarcinoma of the Gastric and Gastro-esophageal Junction

France, Poland, Russian Federation, Taiwan, United States, Hong Kong, Spain, Germany, Italy, Japan, Korea, Republic of, Singapore
Yana Najjar
Merck Sharp & Dohme LLC

Completed

Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b

Melanoma

United States
Eli Lilly and Company

Completed

A Study for Participants With Advanced Cancer

Metastatic Cancer | Advanced Cancer

United States
Memorial Sloan Kettering Cancer Center

Active, not recruiting

A Study of Stereotactic Body Radiotherapy (SBRT) and Surgical Stabilization for People With Cancer That Has Spread to the Bone

Metastatic Cancer

United States
Bristol-Myers Squibb
Nektar Therapeutics

Completed

A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma

Melanoma

Canada, Australia, France, Italy, Brazil, United States, Argentina, Austria, Belgium, Chile, Czechia, Finland, Germany, Greece, Ireland, Israel, Mexico, Netherlands, New Zealand, Poland, Portugal, Romania, Russian Federation, Spain, Sweden and more

Clinical Trials on Unresectable/Metastatic Melanoma in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Finland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations